Robert P Hebbel

List of Publications by Year
in descending order

105 papers	10,351 citations	57758 44 h-index	46799 89 g-index
107 all docs	107 docs citations	107 times ranked	7485 citing authors

#	Article	IF	Citations
1	Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 2000, 105, 71-77.	8.2	1,370
2	Circulating Activated Endothelial Cells in Sickle Cell Anemia. New England Journal of Medicine, 1997, 337, 1584-1590.	27.0	593
3	Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood, 2014, 123, 377-390.	1.4	555
4	Erythrocyte Adherence to Endothelium in Sickle-Cell Anemia. New England Journal of Medicine, 1980, 302, 992-995.	27.0	498
5	Sickle blood contains tissue factorâ€"positive microparticles derived from endothelial cells and monocytes. Blood, 2003, 102, 2678-2683.	1.4	483
6	Abnormal Adherence of Sickle Erythrocytes to Cultured Vascular Endothelium. Journal of Clinical Investigation, 1980, 65, 154-160.	8.2	388
7	Circulating endothelial cells. Thrombosis and Haemostasis, 2005, 93, 228-235.	3.4	337
8	The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy. Microcirculation, 2004, 11, 129-151.	1.8	321
9	The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy. Microcirculation, 2004, 11, 129-151.	1.8	305
10	Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 2000, 96, 2451-2459.	1.4	301
11	Sickle cell disease: renal manifestations and mechanisms. Nature Reviews Nephrology, 2015, 11, 161-171.	9.6	258
12	Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. Journal of Clinical Investigation, 2006, 116, 808-816.	8.2	233
13	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	198
14	Transgenic sickle mice have vascular inflammation. Blood, 2003, 101, 3953-3959.	1.4	195
15	Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 2010, 116, 687-692.	1.4	187
16	The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation, 2004, 11, 129-51.	1.8	183
17	Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 2004, 104, 840-846.	1.4	180
18	Oxidative Stress and Induction of Heme Oxygenase-1 in the Kidney in Sickle Cell Disease. American Journal of Pathology, 2001, 158, 893-903.	3.8	177

#	ARTICLE	IF	CITATIONS
19	Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood, 2010, 116, 456-465.	1.4	159
20	Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood, 2001, 97, 1937-1941.	1.4	146
21	Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2715-H2725.	3.2	142
22	Reconstructing sickle cell disease: A dataâ€based analysis of the â€œhyperhemolysis paradigmâ€•for pulmonary hypertension from the perspective of evidenceâ€based medicine. American Journal of Hematology, 2011, 86, 123-154.	4.1	139
23	Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis, 1999, 3, 147-158.	7.2	138
24	Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radical Biology and Medicine, 2006, 41, 1771-1780.	2.9	126
25	Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB Journal, 2005, 19, 989-991.	0.5	115
26	Sickle Cell Anemia as a Possible State of Enhanced Anti-Apoptotic Tone: Survival Effect of Vascular Endothelial Growth Factor on Circulating and Unanchored Endothelial Cells. Blood, 1999, 93, 3824-3830.	1.4	113
27	NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. American Journal of Physiology - Cell Physiology, 2001, 281, C1422-C1433.	4.6	112
28	Ischemia-reperfusion Injury in Sickle Cell Anemia. Hematology/Oncology Clinics of North America, 2014, 28, 181-198.	2.2	111
29	Transgenic Sickle Mice Are Markedly Sensitive to Renal Ischemia-Reperfusion Injury. American Journal of Pathology, 2005, 166, 963-972.	3.8	108
30	Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H293-H301.	3.2	107
31	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood, 2014, 123, 1747-1756.	1.4	98
32	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. , 1996, 51, 296-301.		83
33	Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radical Biology and Medicine, 2006, 40, 1443-1453.	2.9	79
34	A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 271-292.	0.7	78
35	A Novel Technique for Culture of Human Dermal Microvascular Endothelial Cells under either Serum-Free or Serum-Supplemented Conditions: Isolation by Panning and Stimulation with Vascular Endothelial Growth Factor. Experimental Cell Research, 1997, 230, 244-251.	2.6	77
36	Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness. British Journal of Haematology, 2012, 156, 535-544.	2.5	77

#	Article	IF	Citations
37	The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood, 2010, 115, 2483-2490.	1.4	76
38	Clinical diversity of sickle cell anemia: Genetic and cellular modulation of disease severity. American Journal of Hematology, 1983, 14, 405-416.	4.1	71
39	Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy. American Journal of Hematology, 2004, 77, 117-125.	4.1	67
40	Comparative Oxidation of Hemoglobins A and S. Blood, 1998, 91, 3467-3470.	1.4	66
41	Genetic endothelial systems biology of sickle stroke risk. Blood, 2008, 111, 3872-3879.	1.4	54
42	Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood, 2011, 117, 4125-4133.	1.4	52
43	Microparticles in sickle cell anaemia: promise and pitfalls. British Journal of Haematology, 2016, 174, 16-29.	2.5	50
44	The multifaceted role of ischemia/reperfusion in sickle cell anemia. Journal of Clinical Investigation, 2020, 130, 1062-1072.	8.2	48
45	CD36-positive stress reticulocytosis in sicle cell anemia. Translational Research, 1996, 127, 340-347.	2.3	44
46	Sickle hemoglobin oxygen affinityâ€shifting strategies have unequal cerebrovascular risks. American Journal of Hematology, 2018, 93, 321-325.	4.1	42
47	Inhibition of Sickle Erythrocyte Adhesion to Immobilized Thrombospondin by von Willebrand Factor Under Dynamic Flow Conditions. Blood, 1997, 89, 2560-2567.	1.4	40
48	Nuclear factor-kappa B (NFÎºB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Translational Research, 2010, 155, 170-177.	5.0	40
49	Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. Translational Research, 2005, 145, 204-211.	2.3	39
50	Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. American Journal of Hematology, 2010, 85, 41-45.	4.1	39
51	Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease. Blood, 2021, 137, 1538-1549.	1.4	35
52	H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Frontiers in Pharmacology, 2014, 5, 79.	3.5	32
53	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment, 2017, 166, 541-547.	2.5	32
54	Blood endothelial cells: utility from ambiguity. Journal of Clinical Investigation, 2017, 127, 1613-1615.	8.2	32

#	Article	IF	Citations
55	Anomalous Renal Effects of Tin Protoporphyrin in a Murine Model of Sickle Cell Disease. American Journal of Pathology, 2006, 169, 21-31.	3.8	27
56	Circulating Activated Endothelial Cells in Pediatric Obesity. Journal of Pediatrics, 2010, 157, 547-551.	1.8	26
57	Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6061-6065.	7.1	25
58	A monocyteâ€TNFâ€endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade. American Journal of Hematology, 2017, 92, 1119-1130.	4.1	23
59	Regional and systemic hemodynamic responses following the creation of a murine arteriovenous fistula. American Journal of Physiology - Renal Physiology, 2011, 301, F845-F851.	2.7	21
60	Abnormal Endothelial Gene Expression Associated With Early Coronary Atherosclerosis. Journal of the American Heart Association, 2020, 9, e016134.	3.7	21
61	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 613278.	4.8	20
62	Sickle hemoglobin instability: a mechanism for malarial protection. Redox Report, 2003, 8, 238-240.	4.5	19
63	Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation. Microcirculation, 2006, 13, 489-497.	1.8	19
64	Unique promotion of erythrophagocytosis by malondialdehyde. American Journal of Hematology, 1988, 29, 222-225.	4.1	18
65	Carbon-Fiber Microelectrode Amperometry Reveals Sickle-Cell-Induced Inflammation and Chronic Morphine Effects on Single Mast Cells. ACS Chemical Biology, 2012, 7, 543-551.	3.4	18
66	The systems biologyâ€based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy. American Journal of Hematology, 2009, 84, 543-545.	4.1	15
67	Transport of ¹⁴Câ€deferiprone in normal, thalassaemic and sickle red blood cells. British Journal of Haematology, 1999, 105, 1081-1083.	2.5	14
68	Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus Expressing Interferon-Î² in Preclinical Models of Non-Small Cell Lung Cancer. Translational Oncology, 2020, 13, 100782.	3.7	14
69	Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. Microcirculation, 2004, 11, 99-100.	1.8	14
70	Erythrocyte (Ca+2+Mg+2)-ATPase activity: Increased sensitivity to oxidative stress in glucose-6-phosphate dehydrogenase deficiency. American Journal of Hematology, 1985, 19, 131-136.	4.1	11
71	Reperfusion injury pathophysiology in sickle transgenic mice. Blood, 2000, 96, 314-320.	1.4	10
72	Relationship of Circulating Endothelial Cells With Obesity and Cardiometabolic Risk Factors in Children and Adolescents. Journal of the American Heart Association, 2021, 10, e018092.	3.7	9

#	Article	IF	Citations
73	Reproducibility of circulating endothelial cell enumeration and activation in children and adolescents. Biomarkers in Medicine, 2016, 10, 463-471.	1.4	8
74	Blood Outgrowth Endothelial Cells (BOEC) Contribute to Tumor Vascularization and Can Be Used for Delivery of Cancer Gene Therapy.. Blood, 2004, 104, 3173-3173.	1.4	8
75	Morphine promotes neovascularizing retinopathy in sickle transgeneic mice. Blood Advances, 2019, 3, 1073-1083.	5.2	7
76	Multiple inducers of endothelial <scp>NOS</scp> (<scp>eNOS</scp>) dysfunction in sickle cell disease. American Journal of Hematology, 2021, 96, 1505-1517.	4.1	7
77	Plasma Hemoglobin and Heme Trigger Weibel Palade Body Exocytosis and Vaso-Occlusion in Transgenic Sickle Mice. Blood, 2011, 118, 896-896.	1.4	7
78	SARS-CoV-2 severity in African Americans â€“ A role for Duffy Null?. Haematologica, 2020, 105, 2892.	3.5	7
79	Blood outgrowth endothelial cells overexpressing eNOS mitigate pulmonary hypertension in rats: a unique carrier cell enabling autologous cell-based gene therapy. Translational Research, 2019, 210, 1-7.	5.0	6
80	Interference With TNFÎ± Using Long-Term Etanercept In S+SAntilles Sickle Transgenic Mice Ameliorates Abnormal Endothelial Activation, Vasoocclusion, and Pulmonary Hypertension Including Its Pulmonary Arterial Wall Remodeling. Blood, 2013, 122, 728-728.	1.4	6
81	Selective Enhancement of Contractions to Î±1-adrenergic Receptor Activation in the Aorta of Mice With Sickle Cell Disease. Journal of Cardiovascular Pharmacology, 2011, 57, 263-266.	1.9	5
82	Pathobiology of Sickle Cell Disease. , 2018, , 571-583.		5
83	Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): Evidence for DFO as an extracellular inducer of oxidant stress in RBC. American Journal of Hematology, 2000, 65, 281-284.	4.1	4
84	The missing middle of sickle therapeutics: Multiâ€agent therapy, targeting risk, using biomarkers. American Journal of Hematology, 2018, 93, 1439-1443.	4.1	3
85	Reproducibility of endothelial microparticles in children and adolescents. Biomarkers in Medicine, 2020, 14, 43-51.	1.4	3
86	Oxidative Stress and Vaso-Occlusion in Sickle Cell Disease: Role of Activated Leukocytes and Redox Active Iron.. Blood, 2005, 106, 3165-3165.	1.4	3
87	Genetic Influence on the Systems Biology of Sickle Stroke Risk Detected by Endothelial Gene Expression.. Blood, 2005, 106, 73-73.	1.4	3
88	Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study. Vascular Health and Risk Management, 2018, Volume 14, 205-211.	2.3	2
89	Morphine Stimulates Wound Healing Via Mu Opioid Receptor and Promotes Wound Closure in Sickle Mice. Blood, 2011, 118, 2118-2118.	1.4	2
90	Multiple mechanisms of sickle erythrocyte adherence to vascular endothelial cells. Clinical Hemorheology and Microcirculation, 1992, 12, 185-189.	1.7	1

#	Article	IF	Citations
91	Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A. Blood, 2020, 136, 30-31.	1.4	1
92	Blood Endothelial Cells. , 0, , 1612-1620.		0
93	Sickle Cell Disease Endothelial Activation and Dysfunction. , 2007, , 1352-1359.		0
94	Therapeutic Inhibition of Endothelial Cell Tissue Factor Expression In Vivo by Nitric Oxide and Arginine in Sickle Transgenic Mice.. Blood, 2005, 106, 210-210.	1.4	0
95	Phenotypic Correction of von Willebrand Disease Type 3 Blood-Derived Endothelial Cells with Lentiviral Vectors Expressing von Willebrand Factor.. Blood, 2005, 106, 5522-5522.	1.4	0
96	Hypoxia/Reoxygenation Induced Blood Cell Adhesion in Cerebral Venules of Sickle Cell Transgenic (Î² S) Mice: The Two Faces of eNOS. FASEB Journal, 2006, 20, LB22.	0.5	0
97	Farnesoid X Receptor Dependent Regulation of MMP9 in Blood Outgrowth Endothelial Cells. FASEB Journal, 2006, 20, .	0.5	0
98	Cleaved Kininogen Inhibits Capillary Tube Formation by Circulating Endothelial Cells via inhibiting matrix metalloproteaseâ€2 (MMPâ€2). FASEB Journal, 2007, 21, A194.	0.5	0
99	Association of Inflammatory Transcription Factors in Human Blood Outgrowth Endothelial Cells and Development of Stroke in Sickle Cell Disease. FASEB Journal, 2008, 22, 43-43.	0.5	0
100	Cannabinoids as Analgesics for Pain in Sickle Cell Disease.. Blood, 2009, 114, 822-822.	1.4	0
101	Exhaled Carbon Monoxide as a Marker of Hemolysis In Transgenic Mouse Models of Sickle Cell Anemia.. Blood, 2010, 116, 1642-1642.	1.4	0
102	Association of Non-Healing Wounds, Pain and Neurochemical Alterations In Sickle Cell Disease. Blood, 2010, 116, 842-842.	1.4	0
103	Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. Blood, 2010, 116, 4767-4767.	1.4	0
104	Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. Blood, 2011, 118, 1318-1318.	1.4	0
105	Comparative Oxidation of Hemoglobins A and S. Blood, 1998, 91, 3467-3470.	1.4	0